Shan Riku Sakakibara Sells 4,000 Shares of Billiontoone (NASDAQ:BLLN) Stock

Billiontoone, Inc. (NASDAQ:BLLN) insider Shan Riku Sakakibara sold 4,000 shares of the company’s stock in a transaction on Friday, July 31st. The stock was sold at an average price of $140.21, for a total transaction of $560,840.00. Following the transaction, the insider owned 200,000 shares in the company, valued at approximately $28,042,000. The trade was a 1.96% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Shan Riku Sakakibara also recently made the following trade(s):

• On Thursday, July 9th, Shan Riku Sakakibara sold 8,000 shares of Billiontoone stock. The shares were sold at an average price of $125.00, for a total transaction of $1,000,000.00.
• On Wednesday, June 24th, Shan Riku Sakakibara sold 8,000 shares of Billiontoone stock. The shares were sold at an average price of $110.00, for a total transaction of $880,000.00.
• On Monday, June 8th, Shan Riku Sakakibara sold 8,000 shares of Billiontoone stock. The stock was sold at an average price of $98.22, for a total transaction of $785,760.00.

Billiontoone Trading Up 5.4%

BLLN opened at $149.97 on Thursday. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.92 and a quick ratio of 10.58. Billiontoone, Inc. has a fifty-two week low of $61.96 and a fifty-two week high of $150.44. The firm has a market capitalization of $6.90 billion and a PE ratio of 272.67. The company’s 50-day moving average is $116.73 and its 200 day moving average is $94.26.

Billiontoone (NASDAQ:BLLN) last released its quarterly earnings results on Wednesday, August 5th. The company reported $0.15 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.15. The company had revenue of $109.45 million for the quarter. As a group, research analysts predict that Billiontoone, Inc. will post 0.92 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently commented on BLLN. BTIG Research lowered their price target on Billiontoone from $140.00 to $130.00 and set a “buy” rating for the company in a research report on Thursday, May 7th. Guggenheim initiated coverage on shares of Billiontoone in a report on Monday, June 29th. They set a “buy” rating and a $125.00 price objective on the stock. JPMorgan Chase & Co. upped their target price on shares of Billiontoone from $120.00 to $125.00 and gave the stock an “overweight” rating in a research note on Thursday, May 7th. Finally, Weiss Ratings upgraded shares of Billiontoone from a “sell (d)” rating to a “sell (d+)” rating in a report on Tuesday, June 23rd. Six investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $126.00.

Institutional Trading of Billiontoone

A number of institutional investors and hedge funds have recently modified their holdings of the business. Adams Street Partners LLC bought a new stake in Billiontoone during the fourth quarter worth $140,063,000. Baillie Gifford & Co. bought a new position in Billiontoone in the 4th quarter valued at $103,786,000. Price T Rowe Associates Inc. MD bought a new position in Billiontoone in the 4th quarter valued at $39,717,000. JPMorgan Chase & Co. purchased a new stake in shares of Billiontoone during the 4th quarter valued at $32,078,000. Finally, Wasatch Advisors LP bought a new stake in shares of Billiontoone during the 1st quarter worth $29,179,000.

Key Billiontoone News

Here are the key news stories impacting Billiontoone this week:

• Positive Sentiment: Q2 results met expectations. BillionToOne reported earnings of $0.15 per share, in line with the consensus estimate, while revenue reached $109.45 million. The results support continued demand for the company’s molecular diagnostics platform. BillionToOne Reports Second Quarter 2026 Results and Reiterates 2026 Revenue Guidance
• Positive Sentiment: Full-year revenue guidance was reiterated. Management maintained its 2026 revenue outlook of $450 million to $465 million, broadly consistent with Wall Street’s $453.3 million estimate. While this was not an increase to guidance, the confirmation reduces near-term concerns about a slowdown. BillionToOne Earnings Results
• Neutral Sentiment: Growth opportunities beyond prenatal testing remain an investor focus. Coverage is examining whether BillionToOne can expand its molecular diagnostics business into additional clinical applications, which could provide a longer-term growth engine but has not yet been quantified in the provided reports. Does BillionToOne Have Another Major Growth Engine Beyond Prenatal Testing?
• Negative Sentiment: Insider selling could weigh on sentiment. CEO Oguzhan Atay sold 45,000 shares for approximately $6.17 million, reducing his ownership substantially. Insider Shan Riku Sakakibara also sold 4,000 shares for about $561,000. Both transactions were made under pre-arranged Rule 10b5-1 plans, which makes them less indicative of a sudden loss of confidence, but the sales still increase the stock’s potential overhang. BillionToOne Insider Selling
• Negative Sentiment: Valuation risk remains elevated. BLLN is trading near its 52-week high and at a very high price-to-earnings multiple, while the reported average analyst price target of $126 is below recent trading levels. This leaves the stock vulnerable to profit-taking if future results do not exceed expectations.

Billiontoone Company Profile

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.